Dipeptidyl peptidase 4 (DPP4) inhibitors like sitagliptin are widely used and tolerated in the management of T2DM with minimal or no hypoglycemia as an adverse effect [148, 149]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.